Aspirin slashes risk of gastrointestinal cancer
A large-scale study finds that the long-term use of aspirin cuts the chances of developing digestive cancers almost in half.
Of these, colorectal cancer is thought to be the most widespread in the Western world; in the United States, this form of malignancy is the second leading cause of cancer-related death.
There are a number of things that we can do to prevent cancer, including leading a healthy lifestyle and having regular screenings if we are at risk. In addition to these, an increasing number of studies have been recently pointing to another prevention strategy: the use of aspirin.
In 2009, an international consensus statement said, "Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs [...] on colorectal cancer and probably other cancer types."
Also, the most recent recommendation statement from the U.S. Preventive Services Task Force "recommends initiating low-dose aspirin use for the primary prevention of [colorectal cancer] in adults aged 50 to 59 [...] willing to take low-dose aspirin daily for at least 10 years."
In this context, Prof. Kelvin Tsoi — from the Chinese University of Hong Kong — and his team set out to examine in more detail the preventive effects of...